Compare MGIC & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | RZLT |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 187.3M |
| IPO Year | 1991 | N/A |
| Metric | MGIC | RZLT |
|---|---|---|
| Price | $24.95 | $2.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $18.00 | $9.14 |
| AVG Volume (30 Days) | 27.4K | ★ 6.4M |
| Earning Date | 03-10-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $603,216,000.00 | N/A |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $31.90 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.65 | $1.07 |
| 52 Week High | $28.00 | $11.46 |
| Indicator | MGIC | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 42.12 |
| Support Level | $27.27 | $2.69 |
| Resistance Level | $28.00 | $2.92 |
| Average True Range (ATR) | 0.48 | 0.26 |
| MACD | -0.27 | 0.32 |
| Stochastic Oscillator | 13.79 | 90.22 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.